Can AI Transform South Korea's Bio-Health Sector Using National Data?
Synopsis
South Korea has a unique opportunity to enhance its bio-health industry by leveraging AI and vast bio data, according to a recent Bank of Korea report. With potential for reduced drug development times and increased competitiveness, the nation aims to overcome existing limitations and boost its standing in the global bio-health market.
Key Takeaways
South Korea can enhance its bio-health competitiveness through AI.
AI may reduce drug development timelines by up to 50%.
Access to extensive health data is a strategic advantage.
New regulations could facilitate bio data use for public interest research.
The biotechnology sector is experiencing renewed growth momentum.
Seoul, Feb 9 (NationPress) South Korea has the potential to greatly enhance the competitiveness of its bio-health industry by utilizing its vast and high-quality bio data through artificial intelligence (AI), according to a report released by the Bank of Korea (BOK) on Monday.
The BOK's report highlights that South Korea currently trails behind leading nations in fields such as the development of innovative new drugs and sophisticated medical devices. Meanwhile, the global market is projected to expand at an average annual rate of 5 percent over the next five years due to factors like an aging population.
From 2016 to 2023, South Korea ranked ninth worldwide in the number of bio-health patent applications submitted in the United States, while achieving a fourth-place rank across all sectors, as reported by Yonhap news agency.
According to the report, AI can cut new drug development timelines by as much as 50 percent, drastically reduce research and development costs, and open up new markets. “Given these circumstances, South Korea has a unique opportunity to surpass the limitations of its current industrial ecosystem and outpace leading countries,” it stated.
Significantly, the nation possesses health insurance and clinical data from 50 million individuals, all managed under a single national health insurance system. This is described as “exceptionally rare on a global scale and a strategic asset in the age of AI,” according to the BOK.
To maximize these advantages, the central bank suggested implementing a national bio data approval system. This system would involve an authority conducting preliminary reviews and authorizing data usage only for research that aligns with public interest standards, alongside easing regulations for approved initiatives.
In a related note, South Korea's biotechnology sector saw an output increase of nearly 10 percent in 2024 compared to the previous year, despite ongoing global trade uncertainties, according to industry data.
The biotechnology industry's production reached 22.92 trillion won (approximately US$15.7 billion) in 2024, up from 20.87 trillion won in 2023, as reported by the Ministry of Trade, Industry and Energy (MOTIE), referencing a survey conducted by the Korea Biotechnology Industry Organization (KoreaBIO).
This figure signifies a recovery following a 12 percent year-on-year decline in 2023, indicating a resurgence in growth momentum for the sector.
Point of View
It's clear that South Korea stands at a pivotal juncture in its bio-health journey. By harnessing AI and its unique health data, the nation can not only bolster its industry but also contribute significantly to global health advancements. This proactive approach can position South Korea as a leader in bio-health innovation, benefiting both its economy and the global community.
NationPress
12 May 2026
Frequently Asked Questions
How can AI improve South Korea's bio-health industry?
AI can significantly reduce drug development timelines by up to 50% and lower research costs, thus enhancing the overall competitiveness of the bio-health sector.
What unique data does South Korea possess for AI use?
South Korea has health insurance and clinical data from 50 million individuals under a single national health insurance system, which is a rare and strategic asset.
What recent growth has been observed in the biotechnology sector?
In 2024, the biotechnology industry output grew nearly 10% from the previous year, indicating a recovery and renewed growth momentum.
